National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain

Journal of the American College of Radiology

Volumn 13, Issue 3, 2016, Pages 237-241

  Malayeri, Ashkan A ^a   Brooks, Kristina M ^a   Bryant, L Henry ^a   Evers, Robert ^a   Kumar, Parag ^a   Reich, Daniel S ^a,b   Bluemke, David A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID; CONTRAST MEDIUM;

AUTOPSY; BRAIN FUNCTION; BRAIN METASTASIS; BREAST EXAMINATION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CLINICAL PRACTICE; CLINICAL PROTOCOL; DENTATE NUCLEUS; DISTRIBUTION HALF-LIFE; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG INDICATION; DRUG SAFETY; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL NEUROIMAGING; GLOBUS PALLIDUS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOPATHOLOGY; KIDNEY FUNCTION; MASS SPECTROMETRY; MENINGIOMA; MULTIPLE SCLEROSIS; MUSCLE FUNCTION; NATIONAL HEALTH ORGANIZATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PHAGOCYTOSIS; RADIOLOGICAL PARAMETERS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE; THALAMUS; BRAIN; EVIDENCE BASED MEDICINE; METABOLISM; PRACTICE GUIDELINE; STANDARDS; UNITED STATES;

BRAIN; CONTRAST MEDIA; EVIDENCE-BASED MEDICINE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NATIONAL INSTITUTES OF HEALTH (U.S.); PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84959566503     PISSN: 15461440     EISSN: 1558349X     Source Type: Journal    
DOI: 10.1016/j.jacr.2015.11.009     Document Type: Note

References (21)

1. J.W. Jung, H.R. Kang, M.H. Kim, and et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media Radiology 264 2012 414 422
2. T. Kanda, T. Fukusato, M. Matsuda, and et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy Radiology 276 2015 228 232
3. T. Kanda, K. Ishii, H. Kawaguchi, K. Kitajima, and D. Takenaka High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material Radiology 270 2014 834 841
4. T. Kanda, M. Osawa, H. Oba, and et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration Radiology 275 2015 803 809
5. R.J. McDonald, J.S. McDonald, D.F. Kallmes, and et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging Radiology 275 2015 772 782
6. A. Radbruch, L.D. Weberling, P.J. Kieslich, and et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent Radiology 275 2015 783 791
7. M.S. Nacif, A.E. Arai, J.A. Lima, and D.A. Bluemke Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines J Cardiovasc Magn Reson 14 2012 18
8. American College of Radiology. ACR-SAR-SPR practice parameter for the performance of magnetic resonance imaging (MRI) of the liver. Available at: http://www.acr.org/∼/media/6B520D299C0B4B018A90BE21A79D4F72.pdf. Accessed September 23, 2015.
9. American College of Radiology. ACR-SAR-SPR practice parameter for the performance of magnetic resonance imaging (MRI) of the abdomen (excluding the liver). Available at: http://www.acr.org/∼/media/8f5bc61adb114c5b9e46fe6914461d25.pdf. Accessed September 23, 2015.
10. P. Reimer, and R. Vosshenrich Off-label use of contrast agents Eur Radiol 18 2008 1096 1101
11. +-adenosine triphosphatase of sarcoplasmic reticulum J Biochem 95 1984 661 669
12. E. Husztik, G. Lazar, and A. Parducz Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride Br J Exp Pathol 61 1980 624 630
13. H. Schmitt-Willich Stability of linear and macrocyclic gadolinium based contrast agents Br J Radiol 80 2007 581 582
14. S.K. Morcos Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80 2007 73 76
15. T. Frenzel, P. Lengsfeld, H. Schirmer, J. Hutter, and H.J. Weinmann Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C Invest Radiol 43 2008 817 828
16. Y. Errante, V. Cirimele, C.A. Mallio, V. Di Lazzaro, B.B. Zobel, and C.C. Quattrocchi Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation Invest Radiol 49 2014 685 690
17. C.C. Quattrocchi, C.A. Mallio, Y. Errante, and et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy Invest Radiol 50 2015 470 472
18. J. Ramalho, M. Castillo, M. AlObaidy, and et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents Radiology 276 2015 836 844
19. US Food and Drug Administration. FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM455390.pdf. Accessed September 24, 2015.
20. S. Aime, and P. Caravan Biodistribution of gadolinium-based contrast agents, including gadolinium deposition J Magn Reson Imaging 30 2009 1259 1267
21. H. Ersoy, and F.J. Rybicki Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis J Magn Reson Imaging 26 2007 1190 1197